2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 061

Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey
Abstract Number: 062

Assessment of Barriers and Facilitators in Implementation of the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans
Abstract Number: 063

JAK Inhibition in down Syndrome Associated Arthritis (DA) – Our Experience to Date with Tofacitinib in 5 Patients
Abstract Number: 064

Towards the Development of Composite Parent-Centered Disease Activity Scores for Juvenile Dermatomyositis
Abstract Number: 065

Relationship Between Arthritis and Uveitis Disease Activity in Children with JIA
Abstract Number: 066

Telemedicine Use in the Assessment of Juvenile Myositis: A Mixed-Methods Study of an International Healthcare Provider Experience
Abstract Number: 067

Clinical and Demographic Characteristics of Children with Anti-NMDAR Encephalitis
Abstract Number: 068

Outcomes of Children with Uveitis Associated with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)
Abstract Number: 069

Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratios of Patients with Juvenile Systemic Lupus Erythematosus
Abstract Number: 070

The Impact of the COVID-19 Pandemic on Patients with Juvenile Idiopathic Inflammatory Myopathies
Abstract Number: 071

Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort
Abstract Number: 072

Musculoskeletal Ultrasound Findings in Children with Psoriasis
Abstract Number: 073

Golimumab Therapy in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series Reviewing Safety and Efficacy
Abstract Number: 074

Clinical Characteristics of Juvenile Systemic Sclerosis in Korea: A 30-year Single Center Study
Abstract Number: 075

Emapalumab Treatment Followed by Hematopoietic Stem Cell Transplantation in Systemic Juvenile Idiopathic Arthritis Complicated by Recurrent Macrophage Activation Syndrome

« Previous Page
1
…
3
4
5
6
7
…
10
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].